Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25367828 | 0.98 | P2RX7 (0.53) | P2RX7MAPK1CHRM3TSHRSLC6A1 | |
| Trifluoroacetic Acid SCHEMBL17243108 | 0.85 | F2 (0.42) | P2RX7MAPK1CHRM3TSHRSLC6A1 | |
| SCHEMBL12791545 | 0.81 | P2RX7 (0.48) | P2RX7MAPK1LPLLIPG | |
| Hydrochloric Acid SCHEMBL29043350 | 0.79 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30965858 | 0.76 | P2RX7 (0.80) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL169762 | 0.71 | P2RX7 (1.00) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL457989 | 0.70 | P2RX7 (0.55) | P2RX7MAPK1TSHRBLMLPL | |
| SCHEMBL422542 | 0.69 | P2RX7 (0.89) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL28480332 | 0.69 | P2RX7 (0.44) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL23553614 | 0.69 | P2RX7 (0.48) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025237891-A1 | QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-11-20 | — | — | WO | disclosed |
| US-12448363-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240190864-A1 | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | YA THERAPEUTICS INC (CN) | 2024-06-13 | — | — | US | disclosed |
| EP-3825322-B1 | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOF | CHENGDU SINTANOVO BIOTECHNOLOGY CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | BTK, ABL1, LYN | P2RX7 1390/4885MAPK1 270/4885CHRM3 4518/4885 |
| US-11643436-B2 | Polypeptide compound, pharmaceutical composition, preparation method and application thereof | OPRL1, OPRK1, OPRM1 | P2RX7 129/4885MAPK1 2912/4885CHRM3 196/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | P2RX7 1425/4885MAPK1 2997/4885CHRM3 404/4885 |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | P2RX7 3494/4885MAPK1 3527/4885CHRM3 3586/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | P2RX7 3479/4885MAPK1 3669/4885CHRM3 1171/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | P2RX7 205/4885MAPK1 2923/4885CHRM3 460/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | P2RX7 1964/4885MAPK1 1801/4885CHRM3 2268/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | P2RX7 1390/4885MAPK1 270/4885CHRM3 4518/4885 |
| US-20240190864-A1 | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | BTK, SYK, LYN | P2RX7 1893/4885MAPK1 330/4885CHRM3 4307/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | P2RX7 3479/4885MAPK1 3669/4885CHRM3 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.